Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
about
Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancerMolecular therapeutics in pancreas cancerFrom bench to bedside a comprehensive review of pancreatic cancer immunotherapy.Genetics and biology of pancreatic ductal adenocarcinomaKey players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cellsViro-immune therapy: A new strategy for treatment of pancreatic cancerFueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitorsImmunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trialsImmune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisMolecular Targeted Intervention for Pancreatic CancerPancreatic cancer: optimizing treatment options, new, and emerging targeted therapiesCurrent advances in immunotherapy for pancreatic cancerImmune Checkpoint Blockade in Cancer TherapySpecificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancerImmunotherapy for brain cancer: recent progress and future promiseImmune escape mechanisms as a guide for cancer immunotherapyImmune checkpoint and inflammation as therapeutic targets in pancreatic carcinomaImmune checkpoint therapy for pancreatic cancerTherapeutic cancer vaccines and combination immunotherapies involving vaccinationClinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Antibody Therapies in Cancer.Re-adapting T cells for cancer therapy: from mouse models to clinical trials.Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma.Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations.Stromal reengineering to treat pancreas cancerImmunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulationCurrent and future systemic treatment options in metastatic pancreatic cancer.CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.Gene therapy in pancreatic cancer.Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survivalA feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.Gene and cell therapy for pancreatic cancer.New targeted therapies in pancreatic cancer.Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages
P2860
Q26749451-778E1A36-EFEE-4A90-8CDE-D087BB34B4C6Q26751709-D05B1F4F-ED62-4F96-A1A9-4B0CC02F57B9Q26765123-47567546-897A-4070-8633-19347C7D949EQ26765438-0C122584-3B51-46EB-B904-BA31C5FF456BQ26766065-1680D89B-7973-4437-A021-2649DF658664Q26774641-5830B7A6-71E0-4062-9C47-51E9D569D257Q26778793-8EB8DCD2-D14C-43A4-8B99-933283A03045Q26781538-C43E59BD-1AB5-410C-97D0-C32F1D92EC4EQ26785746-E80A2B42-8CFE-43E3-971B-A043308F6688Q26798453-1169FEA7-6844-41FF-AECF-918A5F5FF14DQ26799714-C2CCB555-E0EF-4025-A6FA-EC93C265A4B7Q26830170-7B7EDA79-DF55-40DE-BC6F-863C743A975EQ26830509-DD226A4F-8D6A-4607-B3DA-4F882B9C977EQ26853171-BAB76080-9D61-48B7-8152-0A061811CAA6Q27015881-E5A1E716-7625-423A-9260-E24438B93600Q27024502-AD0C7489-6B09-4857-9F44-545AB851C400Q28069864-5726478D-3033-4AA1-A3A1-B7B539ED9962Q28078390-8D101FE8-869F-4739-96A2-86B5359619D6Q28397609-496B7BDD-7575-4020-9367-14B044BBD8CEQ30235405-8952FFAE-16A2-4BB3-9967-C7CD472BB850Q30846001-2270F697-8B72-4D1B-8778-108C9371C455Q31104000-56E970B1-3E31-4B65-B6E2-B217912A941FQ33588711-BBEE36FE-DA4C-43B0-9D60-6CBA98CEDA24Q33776367-C392E75D-A5B8-455A-820D-9365F3CB2687Q33779875-EA0DA264-B439-4042-98C7-63EC0B8A72DAQ33827708-CDD314C6-94F2-48E6-B85E-CA8672F43F21Q33848077-04E7C438-EDA4-472A-BC45-A030C38B8D8BQ33948033-CA2548E3-3233-4149-8707-AAAD7D889184Q34279134-AF639C94-3011-4736-AAEA-4A0C3593FBF5Q34302954-49BDAF44-5AE5-42D1-A413-38939240CF1BQ34353251-FCE7D7D2-519A-4ABF-A673-68B1C3ECC456Q34412289-80C07BF9-4393-41C7-AF90-9B8AF5F5786EQ34431614-D80AE39F-D78B-49EB-A342-FD98505CE27FQ34644359-F2B725D3-D06E-4B71-81A5-2602B4B7C565Q35077467-C67CD901-489C-4C8F-983A-72762CF73B84Q35329190-41CBC466-B342-4EC0-AE91-54F3D6B3966FQ35419821-DBCABF7C-CCB6-45A2-AD21-9A48BAEE7A32Q35541787-27401F07-B63C-4611-8AF6-74C2A5C12BE7Q35651453-15FD81B7-A9C5-491F-8B6B-8438D7456416Q35772377-9C9161C9-0DD4-4829-9AF4-DEDCC87A706C
P2860
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Evaluation of ipilimumab in co ...... sly treated pancreatic cancer.
@ast
Evaluation of ipilimumab in co ...... sly treated pancreatic cancer.
@en
Evaluation of ipilimumab in co ...... sly treated pancreatic cancer.
@nl
type
label
Evaluation of ipilimumab in co ...... sly treated pancreatic cancer.
@ast
Evaluation of ipilimumab in co ...... sly treated pancreatic cancer.
@en
Evaluation of ipilimumab in co ...... sly treated pancreatic cancer.
@nl
prefLabel
Evaluation of ipilimumab in co ...... sly treated pancreatic cancer.
@ast
Evaluation of ipilimumab in co ...... sly treated pancreatic cancer.
@en
Evaluation of ipilimumab in co ...... sly treated pancreatic cancer.
@nl
P2093
P2860
P1476
Evaluation of ipilimumab in co ...... sly treated pancreatic cancer.
@en
P2093
Beth Onners
Daniel A Laheru
Elizabeth A Sugar
Jennifer N Uram
Ross C Donehower
P2860
P304
P356
10.1097/CJI.0B013E31829FB7A2
P577
2013-09-01T00:00:00Z